- Specialist drug discovery and development company ImmuPharma said it had entered into a subscription agreement with Lanstead Capital Investors, raising around £2.7m.

New shares in the company were issued at 10p each, respresenting a 27% discount to their closing price on Tuesday.

The found would be used primarily for execution of the company's corporate strategy, ImmuPharma said.

At 2:23pm: [LON:IMM] ImmuPharma PLC share price was -1.64p at 11.96p

Story provided by